Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ide Smets

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2023
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated - NOIde Smets
Multiple Sclerosis and Related Disorders|December 13, 2021
Derisking CD20-therapies for long-term useIde Smets, Gavin Giovannoni
Practical Neurology|February 25, 2021
Amyloidoma mimicking multiple sclerosisIde Smets, Silvia Marino, Gavin Giovannoni
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 13, 2022
Should anti-CD20 be used as an immune reconstitution therapy?Ide Smets, Beatrijs Wokke, Joost Smolders
Therapeutic Advances in Neurological Disorders|September 23, 2025
Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosisJoost Smolders, Ide Smets, Beatrijs Wokke
Acta Orthopaedica Belgica|July 25, 2012
Chronic anterior shoulder dislocation: aspects of current management and potential complicationsFilip Verhaegen, Ide Smets, Marc Bosquet, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 11, 2024
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence modelIde Smets, Matthijs Versteegh, Simone Huygens, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 6, 2018
Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variationKelly Hilven, Marijne Vandebergh, Ide Smets, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 2, 2023
Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence modelIde Smets, Matthijs Versteegh, Simone Huygens, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2020
Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosisBenjamin M Jacobs, Ide Smets, Gavin Giovannoni, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2023
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated - NOIde Smets
Multiple Sclerosis and Related Disorders|December 13, 2021
Derisking CD20-therapies for long-term useIde Smets, Gavin Giovannoni
Practical Neurology|February 25, 2021
Amyloidoma mimicking multiple sclerosisIde Smets, Silvia Marino, Gavin Giovannoni
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 13, 2022
Should anti-CD20 be used as an immune reconstitution therapy?Ide Smets, Beatrijs Wokke, Joost Smolders
Therapeutic Advances in Neurological Disorders|September 23, 2025
Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosisJoost Smolders, Ide Smets, Beatrijs Wokke
Acta Orthopaedica Belgica|July 25, 2012
Chronic anterior shoulder dislocation: aspects of current management and potential complicationsFilip Verhaegen, Ide Smets, Marc Bosquet, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 11, 2024
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence modelIde Smets, Matthijs Versteegh, Simone Huygens, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 6, 2018
Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variationKelly Hilven, Marijne Vandebergh, Ide Smets, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 2, 2023
Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence modelIde Smets, Matthijs Versteegh, Simone Huygens, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2020
Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosisBenjamin M Jacobs, Ide Smets, Gavin Giovannoni, et al.
Pageof 3